Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Stock Chart & Stats
$190.86
-$2.82(-3.64%)
At close: 4:00 PM EST
$190.86
-$2.82(-3.64%)
Day’s Range― - ―
52-Week Range$26.70 - $206.71
Previous CloseN/A
Volume51.58K
Average Volume (3M)1.39M
Market Cap
$4.77B
Enterprise Value$898.07M
Total Cash (Recent Filing)$267.16M
Total Debt (Recent Filing)$436.00K
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Mar 04, 2026EPS Estimate
-3.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding25,007,172
10 Day Avg. Volume951,881
30 Day Avg. Volume1,390,952
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.09
Price to Sales (P/S)161.13
P/FCF Ratio-10.46
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue120.34
Enterprise Value/Gross Profit-3.77
Enterprise Value/Ebitda-3.11
Forecast
1Y Price Target
$327.08Price Target Upside71.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-13.06
Revenue Forecast (FY)$325.93K
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPraxis announced positive results from both Phase 3 Essential3 ET studies of ulixacaltamide, showing robust, statistically significant, and consistent improvements.
Financial StrengthPraxis has a strong financial position with an expected operational expense runway into 2028, supported by a recent equity raise.
Market OpportunityUlixacaltamide is positioned with commercial potential in the Essential Tremor market, addressing a massive unmet need and commercial opportunity.
Bears Say
Adverse EffectsThe most common adverse effects of ulixa were dizziness and brain fog, which led to a discontinuation rate of approximately 35-38%.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $206.71 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $4.77B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Mar 04, 2026 which is in 98 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Nov 05, 2025. The company reported -$3.36 earnings per share for the quarter, beating the consensus estimate of -$3.466 by $0.106.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.09.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 25,007,172 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.36 in its last earnings report, beating expectations of -$3.466. Following the earnings report the stock price went down -4.14%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$327.08 (71.37% Upside)
$327.08 (71.37% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.41%
12-Months-Change
Fundamentals
Return on Equity
-75.20%
Trailing 12-Months
Asset Growth
-4.77%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines (PRAX) is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with neuropsychiatric diseases. The company specializes in precision medicine approaches to address conditions such as epilepsy, depression, and anxiety disorders, leveraging its proprietary drug discovery platforms and advanced clinical trial methodologies. Praxis aims to bring innovative treatments to market that are tailored to the unique genetic and biological profiles of individual patients.
PRAX Company Deck
PRAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$327.08
▲(71.37% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
18.54% Insiders
13.97% Mutual Funds
5.14% Other Institutional Investors
50.43% Public Companies and Individual Investors